Go Deep
Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,639 | -10.1 | 4.11 | 0.34 | 153.33 |
| Oct 2026 | 18,671 | -10.0 | 4.08 | 0.34 | 151.92 |
| Oct 2026 | 18,513 | -10.3 | 4.21 | 0.34 | 156.69 |
| Oct 2026 | 18,922 | -9.5 | 3.88 | 0.34 | 143.97 |
| Oct 2026 | 18,828 | -9.7 | 3.95 | 0.34 | 146.97 |
| Oct 2026 | 18,734 | -9.9 | 4.03 | 0.34 | 149.81 |
| Oct 2026 | 18,796 | -9.8 | 3.98 | 0.34 | 147.55 |
| Oct 2026 | 19,017 | -9.3 | 3.80 | 0.34 | 140.64 |
Lexicon Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 692,000.0 | 21,102,000.0 | 5,493,000.0 | 14,182,000.0 |
| Net Profit | -31,775,000.0 | -1,043,000.0 | -15,530,000.0 | -12,769,000.0 |
| EPS | -0.1 | 0.0 | -0.0 | -0.0 |
Lexicon Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 49,803,000.0 | 31,081,000.0 | 1,204,000.0 | 139,000.0 | — |
| Net Profit | -50,341,000.0 | -200,403,000.0 | -177,119,000.0 | -101,944,000.0 | — |
| EPS | -0.1 | -0.6 | -0.8 | -0.6 | — |
Lexicon Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 184,987,000.0 | 298,420,000.0 | 229,429,000.0 | 194,299,000.0 | — |
| Total Liabilities | 77,449,000.0 | 152,470,000.0 | 136,319,000.0 | 77,175,000.0 | — |
| Total Equity | 107,538,000.0 | 145,950,000.0 | 93,110,000.0 | 117,124,000.0 | — |
Owes vs Owns
Lexicon Pharmaceuticals, Inc. owed $0.30 for every $1 it owned in Jun 2026, down from $0.40 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.30× | 0.42× | 0.51× | 0.59× | 0.40× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Lexicon Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 52.0%Receivables 1.3%Fixed assets (tangible) 5.0%Intangible assets 24.1%Other assets 17.5%
How it's funded — Dec 2025
Short-term debt 2.5%Long-term debt 26.7%Payables 1.7%Other liabilities 11.0%Shareholders' equity 58.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 96.2 | 238.0 | 170.0 | 138.4 |
| Receivables | 2.4 | 3.5 | 1.0 | 0.0 |
| Inventory | 0.3 | 0.2 | 0.4 | 0.0 |
| Fixed assets (tangible) | 9.2 | 7.3 | 7.5 | 8.5 |
| Intangible assets | 44.5 | 44.5 | 44.5 | 44.5 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 32.4 | 4.9 | 6.0 | 2.9 |
| Liabilities & equity | ||||
| Short-term debt | 4.6 | 1.2 | 1.3 | 1.3 |
| Long-term debt | 49.4 | 100.3 | 99.5 | 48.6 |
| Payables | 3.1 | 14.8 | 14.4 | 10.4 |
| Other liabilities | 20.4 | 36.2 | 21.1 | 16.9 |
| Shareholders' equity | 107.5 | 145.9 | 93.1 | 117.1 |
| Net tangible assets | 63.0 | 101.4 | 48.6 | 72.6 |
Lexicon Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -67,851,000.0 | -178,780,000.0 | -161,897,000.0 | -88,851,000.0 | — |
| Investing Activities | 113,020,000.0 | -15,378,000.0 | -49,943,000.0 | -71,078,000.0 | — |
| Financing Activities | -48,499,000.0 | 238,349,000.0 | 187,960,000.0 | 142,209,000.0 | — |